A5008098651- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- PARP inhibition in cancer therapy
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Chronic Lymphocytic Leukemia Research
- BRCA gene mutations in cancer
- Cancer-related Molecular Pathways
- Breast Lesions and Carcinomas
- Cancer Diagnosis and Treatment
- Estrogen and related hormone effects
- DNA Repair Mechanisms
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- PI3K/AKT/mTOR signaling in cancer
- RNA modifications and cancer
- Genetic factors in colorectal cancer
- MicroRNA in disease regulation
- Metastasis and carcinoma case studies
Chinese Academy of Medical Sciences & Peking Union Medical College
2016-2025
Guangzhou University
2025
Shanghai Changzheng Hospital
2025
Jilin City Central Hospital
2025
Peking Union Medical College Hospital
2012-2024
Northeast Forestry University
2024
Guangdong Academy of Medical Sciences
2023
Southern Medical University
2023
Guangdong Provincial People's Hospital
2023
Seoul National University Hospital
2012-2022
Olaparib is an oral poly(adenosine diphosphate–ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation.
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after a combination of anti-HER2 antibodies and taxane.We conducted phase 3, multicenter, open-label, randomized trial to compare efficacy safety trastuzumab deruxtecan (a HER2 antibody-drug conjugate) those in HER2-positive previously treated taxane. The primary end point was progression-free survival (as...
In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician's choice (TPC) in patients a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC). We now report planned final overall (OS) results, describe most common adverse events (AEs) better understand tolerability this population.
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, clinically meaningful overall (OS) effect PD-L1-positive aTNBC. The KEYNOTE-355 trial adding pembrolizumab to chemotherapy aTNBC similar PFS effects. IMpassion131...
Advanced breast cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality life. Due continuous research, several advances have been made, particularly for the human epidermal growth factor receptor 2 (HER-2)-positive luminal-like subtypes. Notwithstanding these advances, median overall survival patients with ABC only 2–3 years, although range wide [1–5], may be longer treated in specialized institutions [6].
In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with checkpoint inhibitors is still not very clear. We utilize single-cell RNA- and ATAC-sequencing to examine immune cell dynamics in 22 patients advanced TNBC treated paclitaxel or its combination anti-PD-L1 atezolizumab. demonstrate that high levels baseline CXCL13+ T cells are linked proinflammatory features macrophages can predict effective responses therapy. responsive patients, lymphoid tissue inducer (LTi)...
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality life. Due continuous research, several advances have been made, particularly for the HER-2-positive Luminal-like subtypes. Notwithstanding these advances, median overall survival patients with ABC only 2–3 years, although range wide [1–5], may be longer treated in specialized institutions [6]. Implementation current knowledge highly variable among...
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, it is remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5,6].
Purpose This phase I study assessed the safety, tolerability, pharmacokinetics, antitumor activity, and predictive biomarkers of pyrotinib, an irreversible pan-ErbB inhibitor, in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Patients Methods Pyrotinib was administered continuously, orally, once per day to who did not have prior exposure tyrosine kinase inhibitors HER2. Planned dose escalation 80, 160, 240, 320, 400, 480 mg. For...
Purpose: The current management of advanced esophageal squamous cell carcinoma (ESCC) remains unsatisfactory. We investigated the safety, efficacy, and biomarkers SHR-1210, an anti-PD-1 antibody, in patients with recurrent or metastatic ESCC.Experimental Design: This study was part a phase I trial China. Patients ESCC who were refractory intolerant to previous chemotherapy enrolled. Eligible received intravenous SHR-1210 at dose 60 mg, escalation 200 400 mg (4-week interval after first...
Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)–positive, human epidermal growth factor 2 (HER2)–negative advanced breast cancer. Whether this cancer extends early is unclear. Download PDF of the Research Summary. In international, open-label, randomized, phase 3 trial, we randomly assigned HR-positive, HER2-negative 1:1 ratio receive ribociclib (at dose 400 mg per day for weeks, followed by 1 week off, years) plus nonsteroidal...
LBA500 Background: RIB + ET has demonstrated significant survival benefits in pre- and postmenopausal pts with HR+/HER2− metastatic BC. To investigate whether also improves outcomes early BC (EBC), the Phase III NATALEE trial (NCT03701334) evaluated adjuvant a broad population of stage II or EBC at risk for recurrence, including no nodal involvement (N0). As extended duration tx is crucial to prolong cell cycle arrest drive more tumor cells into senescence death, 3-y dose 400 mg was chosen...
To characterize the clinical and pathological features survival of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer in China.The China National Cancer Center database was used to identify 1,433 metastatic HER2-negative disease diagnosed between 2005 2015. Clinicopathological features, survival, prognosis information were extracted. Overall (OS) estimated using Kaplan-Meier method compared log-rank test. Prognostic factors associated OS analyzed Cox regression...